(Q44364497)

2 December 2017

title

Incidence of atypical nontraumatic diaphyseal fractures of the femur (English)

1 reference

2 December 2017

1 reference

Richard M Dell

1

1 reference

2 December 2017

Annette L Adams

2

1 reference

2 December 2017

Denise F Greene

3

1 reference

2 December 2017

Tadashi T Funahashi

4

1 reference

2 December 2017

Stuart L Silverman

5

1 reference

2 December 2017

Eric O Eisemon

6

1 reference

2 December 2017

Hui Zhou

7

1 reference

2 December 2017

Raoul J Burchette

8

1 reference

2 December 2017

Susan M Ott

9

1 reference

2 December 2017

publication date

1 December 2012

1 reference

Journal of Bone and Mineral Research

2 December 2017

published in

1 reference

2 December 2017

volume

27

1 reference

2 December 2017

issue

12

1 reference

2 December 2017

page(s)

2544-2550

1 reference

Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis

2 December 2017

cites work

1 reference

Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution

21 January 2018

1 reference

Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate

21 January 2018

1 reference

Low-energy femoral shaft fractures associated with alendronate use.

21 January 2018

1 reference

Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies

21 January 2018

1 reference

Femoral Insufficiency Fractures Associated with Prolonged Bisphosphonate Therapy

21 January 2018

1 reference

Incidence and demography of femur fractures with and without atypical features

21 January 2018

1 reference

Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates

21 January 2018

1 reference

Trends in Incidence of Subtrochanteric Fragility Fractures and Bisphosphonate Use Among the US Elderly, 1996–2007

21 January 2018

1 reference

Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis

21 January 2018

1 reference

Bisphosphonate Use and the Risk of Subtrochanteric or Femoral Shaft Fractures in Older Women

21 January 2018

1 reference

Utility of automated data in identifying femoral shaft and subtrochanteric (diaphyseal) fractures

21 January 2018

1 reference

Increasing occurrence of atypical femoral fractures associated with bisphosphonate use.

21 January 2018

1 reference

Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trials

21 January 2018

1 reference

Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures .

21 January 2018

1 reference

Fragility fractures of the hip and femur: incidence and patient characteristics

21 January 2018

1 reference

Displaced fatigue fractures of the femoral shaft

21 January 2018

1 reference

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

21 January 2018

1 reference

Ten years' experience with alendronate for osteoporosis in postmenopausal women

21 January 2018

1 reference

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

21 January 2018

1 reference

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JBMR.1719

1 reference

2 December 2017

1 reference